科技创新中心

Science and Technology Innovation Center，Guangzhou University of Chinese Medicine

杏林后备人才

姓名：陈桐楷

专业：中药学

研究方向：纳米药物治疗肿瘤和脑部疾病

教育背景及工作经历：

2013年9月~2017年7月：澳门大学，生物医药专业，博士

2017年9月~至今：广州中医药大学，临床药理研究所，副研究员

主要承担项目：

1.高水平大学建设杏林人才科研配套经费，靶向纳米药物治疗脑部疾病，2017/09~2020/09，40万，项目负责人。

2.广东省自然科学基金，小粒径纳米晶体/聚合物胶束的跨膜转运特性及其在斑马鱼体内的吸收、分布、消除过程研究，2018A030310623，2018/05～2021/04，10万，项目负责人。

3.广东省医学科研基金，离子交换树脂缓释混悬剂的关键技术研究，A2019027，2019/07~2021/06，0.5万，项目负责人。

代表性论文（近三年）：

1.Tongkai Chen, Bing He, Jingsong Tao, Yuan He, Hailiang Deng, Xueqing Wang, Ying Zheng.Application of Förster Resonance Energy Transfer (FRET) Technique to Elucidate Intracellular andIn VivoBiofate of Nanomedicines.Advanced Drug Delivery Reviews, 2019, In Press. (IF: 15.52)

2.Sha Xiong^#, Wei Liu^#, Yile Zhou, Yousheng Mo, Yao Liu, Xiaojia Chen, Huafeng Pan, Dongsheng Yuan*, Qi Wang*,Tongkai Chen*. Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation.Asian Journal of Pharmaceutical Sciences, 2019, In Press. (IF: 4.56)

3.Sha Xiong^#, Wei Liu^#, Dongli Li^#, Xiaojia Chen, Fang Liu, Dongsheng Yuan, Huafeng Pan, Qi Wang, Shuhuan Fang*,Tongkai Chen*. Oral delivery of Puerarin nanocrystals to improve brain accumulation and anti-Parkinsonian efficacy.Molecular Pharmaceutics, 2019, 16: 1444-1455. (IF: 4.55)

4.Tongkai Chen, Jian Li, Ting Chen, Changquan Calvin Sun, Ying Zheng. Tablets of multi-unit pellet system for controlled drug delivery.Journal of Controlled Release,2017, 262: 222-231.(IF: 7.90)

5.Tongkai Chen, Chuwen Li, Ye Li, Xiang Yi, Ruibing Wang, Simon Ming-Yuen Lee, Ying Zheng. Small-sized mPEG-PLGA nanoparticles of Schisantherin A with sustained release for enhanced brain uptake and anti-Parkinsonian activity.ACS Applied Materials & Interfaces, 2017, 9(11): 9516-9527. (IF:8.45)

6.Tongkai Chen, Ye Li, Chuwen Li, Xiang Yi, Simon Ming-Yuen Lee, Ying Zheng. Pluronic P85/F68 micelles of baicalein could interfere with mitochondria to overcome multidrug resistance-associated protein 2 (MRP2)-mediated efflux and offer improved anti-Parkinsonian activity.Molecular Pharmaceutics, 2017, 14: 3331-3342. (IF: 4.55)